TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8974721

Group type: EXPERIMENTAL
Intervention: EGb 761 infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 40
Study: 1453510

Group type: EXPERIMENTAL
Intervention: High frequency two-way jet ventilation (HFTJV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: High frequency jet ventilation (HFJV)
Number of subjects: 10
Study: 6367599

Group type: EXPERIMENTAL
Intervention: Tromaril (enfenamic acid)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tromaril
Number of subjects: 30
Study: 30504071

Group type: EXPERIMENTAL
Intervention: Concomitant psychiatric disorders in children with ASD
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: ADHD
Number of subjects: 658
Study: 28195950

Group type: EXPERIMENTAL
Intervention: Videoconferencing administration of the La Trobe Communication Questionnaire (LCQ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: In-person administration of the La Trobe Communication Questionnaire (LCQ)
Number of subjects: 20
Study: 27276842

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg (2 ml) intravenous 60-90 minutes before surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline 2 ml 60-90 minutes before surgery
Number of subjects: 80
Study: 23937657

Group type: EXPERIMENTAL
Intervention: Cold atmospheric argon plasma treatment for 2 minutes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (argon gas) treatment for 2 minutes
Number of subjects: 40
Study: 21320138

Group type: EXPERIMENTAL
Intervention: ADX10059 120 mg b.d.
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 19153758

Group type: EXPERIMENTAL
Intervention: 12% O(2) exposure
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 15% O(2) exposure
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 21% O(2) exposure
Number of subjects: 10
Study: 16984929

Group type: EXPERIMENTAL
Intervention: valsartan
Number of subjects: 14703

Group type: EXPERIMENTAL
Intervention: captopril
Number of subjects: 14703

Group type: EXPERIMENTAL
Intervention: combination of valsartan and captopril
Number of subjects: 14703

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14703
Study: 15006283

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 8171

Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 8171

Group type: EXPERIMENTAL
Intervention: Beta-carotene
Number of subjects: 8171

Group type: EXPERIMENTAL
Intervention: Folic acid/vitamin B(6)/vitamin B(12)
Number of subjects: 8171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8171

Group type: COMPARATOR
Intervention: Placebo for folic acid/vitamin B(6)/vitamin B(12)
Number of subjects: 8171
Study: 11317143

Group type: EXPERIMENTAL
Intervention: Running (4-5 km)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (sedentary)
Number of subjects: 17
Study: 9734406

Group type: EXPERIMENTAL
Intervention: Computer-based visual restitution training (VRT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 38
Study: 7662044

Group type: EXPERIMENTAL
Intervention: Acamprosate 2.0 g/day (high dose group)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Acamprosate 1.3 g/day (low dose group)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Acamprosate groups (both doses)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 538
Study: 2751161

Group type: EXPERIMENTAL
Intervention: Sulfuric acid aerosols (20 microns)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfuric acid aerosols (10 microns)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfuric acid aerosols (1 micron)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfuric acid exposures (in asthmatics)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions (purified water aerosols)
Number of subjects: 0
Study: 339785

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Simulated acupuncture
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nebulized saline
Number of subjects: 12

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 12
Study: 30738826

Group type: EXPERIMENTAL
Intervention: Discontinuation of antihypertensive medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study: 28713032

Group type: EXPERIMENTAL
Intervention: Adaptive Disclosure (AD) therapy
Number of subjects: 186

Group type: COMPARATOR
Intervention: Present-Centered Therapy (PCT)
Number of subjects: 186
Study: 25312783

Group type: EXPERIMENTAL
Intervention: Triple-combination therapy with Pre + TAC + CTX
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Triple-combination therapy with Pre + TAC + MMF
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Triple-combination therapy with Pre + TAC + LEF
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Triple-combination therapy with Pre + TAC + CTX/MMF/LEF
Number of subjects: 18
Study: 23168287

Group type: EXPERIMENTAL
Intervention: VWF multimer ratio
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: PFA‐CADP
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: VWF high‐molecular‐weight multimers
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: VWF latex agglutination immunoturbidic activity/VWF antigen ratio
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Bleeding
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Symptoms
Number of subjects: 66
Study: 21256669

Group type: EXPERIMENTAL
Intervention: Sterile sodium chloride (NaCl) 0.9% irrigation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Tap water (H2O) irrigation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sterile sodium chloride (NaCl) 0.9% solution
Number of subjects: 23
Study: 19300114

Group type: EXPERIMENTAL
Intervention: Supportive measures (structured physician‐patient interaction, printed information about hypertension, reminder stickers, 24 h timer, home BP measurement device)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Supportive measures
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard care (no supportive measures)
Number of subjects: 202
Study: 16999640

Group type: EXPERIMENTAL
Intervention: Genetic counseling intervention
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 14607553

Group type: EXPERIMENTAL
Intervention: hMG
Number of subjects: 2030

Group type: COMPARATOR
Intervention: recombinant FSH
Number of subjects: 2030
Study: 10487373

Group type: EXPERIMENTAL
Intervention: 1-year moderate intensity aerobic and strength training exercise program (monitored group exercise sessions plus home exercise)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control program (stretching classes)
Number of subjects: 168
Study: 9551128

Group type: EXPERIMENTAL
Intervention: Balinese dance exercise 3 x 50 min per week for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study: 2006658

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 7272177

Group type: EXPERIMENTAL
Intervention: Caroxazone 200 mg three times daily
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Caroxazone treatment
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Post-treatment (after discontinuation of caroxazone)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Caroxazone
Number of subjects: 6
Study: 2418305

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 0
Study: 29931594

Group type: EXPERIMENTAL
Intervention: Telotristat ethyl 250 mg three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27331882

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25295771

Group type: EXPERIMENTAL
Intervention: mHealth technology with tailored physical activity prescription targeting changes to daily exercise, sedentary behavior, or both
Number of subjects: 45
Study: 22503510

Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 70
Study: 20453709

Group type: EXPERIMENTAL
Intervention: GPO-VIR S7 chewable tablets
Number of subjects: 34

Group type: COMPARATOR
Intervention: Liquid formulations
Number of subjects: 34
Study: 18197995

Group type: EXPERIMENTAL
Intervention: Dietitian-led intensive lifestyle intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 50
Study: 16077744

Group type: EXPERIMENTAL
Intervention: TPN with 1.5 g/kg body weight of a standard amino acid
Number of subjects: 24

Group type: COMPARATOR
Intervention: TPN with 1.2 g/kg body weight of a standard amino acid and 0.3 g/kg L-alanine-L-glutamine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: TPN with glutamine supplementation (gln+)
Number of subjects: 24

Group type: COMPARATOR
Intervention: TPN without glutamine supplementation (gln-)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: gln+ group
Number of subjects: 24

Group type: COMPARATOR
Intervention: gln- group
Number of subjects: 24
Study: 12208318

Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10507486

Group type: EXPERIMENTAL
Intervention: Cyclosporine microemulsion (CsA-NL)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Oil-based cyclosporine (CsA-SM)
Number of subjects: 380
Study: 8622024

Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2 and cyclophosphamide 1,250 mg/m2 with filgrastim 5 microG/kg/d
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Paclitaxel administered first
Number of subjects: 37

Group type: COMPARATOR
Intervention: Cyclophosphamide administered first
Number of subjects: 37
Study: 2014934

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 220 micrograms/day
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 440 micrograms/day
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 110 micrograms/day
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 6130038

Group type: EXPERIMENTAL
Intervention: Metoprolol (150 mg per day)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg per day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Metoprolol and Propranolol
Number of subjects: 7
Study: 30553916

Group type: EXPERIMENTAL
Intervention: D2 receptor antagonists (three different types)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29598883

Group type: EXPERIMENTAL
Intervention: Vitamin D (1000 IU/day)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Omega-3 (1000 mg/day)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both omega-3 (1000 mg/day) and vitamin D (1000 IU/day)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 26060209

Group type: EXPERIMENTAL
Intervention: Electrocardiographic evaluations
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Electrophysiological evaluations
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Electrophysiological study
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Total study group follow-up
Number of subjects: 45
Study: 24837794

Group type: EXPERIMENTAL
Intervention: Loading dose (2 initial days of double maintenance dose)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Maintenance dose (most recent maintenance dose)
Number of subjects: 98
Study: 22644425

Group type: EXPERIMENTAL
Intervention: US fusion biopsy with MRI (n=16)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: US fusion biopsy with CT (n=15)
Number of subjects: 47

Group type: COMPARATOR
Intervention: CT-guided biopsy (n=16)
Number of subjects: 47
Study: 19892836

Group type: EXPERIMENTAL
Intervention: Mixed meal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mixed meal in controls
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mixed meal in diabetic patients (with and without insulin)
Number of subjects: 30
Study: 18541604

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 16364

Group type: COMPARATOR
Intervention: Untreated Control
Number of subjects: 16364
Study: 16195001

Group type: EXPERIMENTAL
Intervention: High-intensity intermittent running (Loughborough Intermittent Shuttle Test) in hot conditions
Number of subjects: 9
Study: 12035937

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.02 mg/kg po at ‐90 min)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 10591421

Group type: EXPERIMENTAL
Intervention: Lactose-free (L-) formula
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard lactose-containing (L+) formula
Number of subjects: 41
Study: 8696546

Group type: EXPERIMENTAL
Intervention: Normalization and maintenance of gastric mucosal pH (pHi) at or above 7.3
Number of subjects: 57

Group type: COMPARATOR
Intervention: Maintenance of oxygen delivery index of 600 or an oxygen consumption index of greater than 150
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 57
Study: 2008006

Group type: EXPERIMENTAL
Intervention: Amnioinfusion treatment group (n = 19)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 35
Study: 6283982

Group type: EXPERIMENTAL
Intervention: Cytomegalovirus immune plasma
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 29052071

Group type: EXPERIMENTAL
Intervention: VBLaST training group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: FLS training group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 26955742

Group type: EXPERIMENTAL
Intervention: ATP (40 mg/day) for rabbits; ATP (60 mg twice a day) for patients
Number of subjects: 44

Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 44
Study: 25296243

Group type: EXPERIMENTAL
Intervention: Low-residue diet (LRD)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Clear liquid diet (CLD)
Number of subjects: 200
Study: 22927836

Group type: EXPERIMENTAL
Intervention: Bifid Triple Viable and Etiasa
Number of subjects: 82

Group type: COMPARATOR
Intervention: Etiasa
Number of subjects: 82
Study: 20167591

Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta-1a
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control (not currently using intramuscular interferon beta-1a)
Number of subjects: 172
Study: 16923824

Group type: EXPERIMENTAL
Intervention: Subacromial infusion of 0.5% bupivacaine (group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous injection of fentanyl and ketorolac tromethamine (group 2)
Number of subjects: 40
Study: 16234453

Group type: EXPERIMENTAL
Intervention: Intracameral recombinant tissue plasminogen activator (r-TPA) 20 microg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Balanced salt solution (Control)
Number of subjects: 26
Study: 12142199

Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy (group I)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional treatment (group II)
Number of subjects: 150
Study: 9466023

Group type: EXPERIMENTAL
Intervention: Lidocaine 2%-buprenorphine at a rate of 6.3 ml.hr‐1 (2% group, n = 13)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lidocaine 6%-buprenorphine at a rate of 2.1 ml.hr‐1 (6% group, n = 15)
Number of subjects: 28
Study: 8589318

Group type: EXPERIMENTAL
Intervention: Low-protein diet with keto acids supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-protein diet without keto acids supplementation
Number of subjects: 12
Study: 2669939

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 236805

Group type: EXPERIMENTAL
Intervention: Alclofenac
Number of subjects: 109

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 109
Study: 31629703

Group type: EXPERIMENTAL
Intervention: Ezetimibe (Eze) + statins (simvastatin 10 mg, 20 mg, 40 mg, 80 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ezetimibe (Eze) + atorvastatin (20 mg, 40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statin monotherapy (simvastatin, atorvastatin)
Number of subjects: 0
Study: 27090395

Group type: EXPERIMENTAL
Intervention: High-dose resistance training (RT) maintenance intervention
Number of subjects: 123

Group type: COMPARATOR
Intervention: Low-dose resistance training (RT) maintenance intervention
Number of subjects: 123
Study: 24822235

Group type: EXPERIMENTAL
Intervention: Tizanidine 4 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 10 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 22281114

Group type: EXPERIMENTAL
Intervention: Py's technique (isoelastic pinning)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Kapandji's technique (intrafocal pinning)
Number of subjects: 97
Study: 20078915

Group type: EXPERIMENTAL
Intervention: Training with an electronic disaster simulation tool (disastermed.ca)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (nondisaster setting simulation)
Number of subjects: 22
Study: 19198698

Group type: EXPERIMENTAL
Intervention: Controlled-release fluvoxamine (CR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release fluvoxamine (IR)
Number of subjects: 0
Study: 16807626

Group type: EXPERIMENTAL
Intervention: Resistance training (3 times weekly at 60% of one-repetition maximum, 9 resistance exercises, 3 sets of 15 repetitions each)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 28
Study: 14568830

Group type: EXPERIMENTAL
Intervention: 532-nm KTP laser alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 1064-nm Nd:YAG laser alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combination of KTP and Nd:YAG lasers
Number of subjects: 150
Study: 11317400

Group type: EXPERIMENTAL
Intervention: Composite resin (1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Composite resin using the incremental technique (2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Direct composite inlay (5)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ceramic insert (6)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cerafil inlay (7)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Experimental glass‐fiber‐reinforced composite resins (3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Experimental direct filling using Dyract AP compomer (8)
Number of subjects: 80
Study: 8823230

Group type: EXPERIMENTAL
Intervention: Bosentan (oral) at doses of 3, 10, 30, 100, 300, 600, 1200, and 2400 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bosentan (intravenous) at doses of 10, 50, 250, 500, and 750 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bosentan (oral)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bosentan (intravenous)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7949478

Group type: EXPERIMENTAL
Intervention: bath-PUVA therapy (30-min baths in 0.0003% 8-MOP aqueous solution, 4 times a week)
Number of subjects: 22

Group type: COMPARATOR
Intervention: oral administration of 8-MOP
Number of subjects: 22
Study: 3280317

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 40 mg three times daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg three times daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31702655

Group type: EXPERIMENTAL
Intervention: SIP with concurrent auditory cues (AC condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SIP without auditory cues (NC condition)
Number of subjects: 0
Study: 28598705

Group type: EXPERIMENTAL
Intervention: Individual CBT combined with TAU (n=59)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Group CBT combined with TAU (n=86)
Number of subjects: 181

Group type: COMPARATOR
Intervention: TAU only (n=36)
Number of subjects: 181
Study: 27341793

Group type: EXPERIMENTAL
Intervention: Intervention sites with quarterly workplace assessments and offering HIV treatment at OHUs
Number of subjects: 1372

Group type: COMPARATOR
Intervention: Comparison sites with bi-annual infection control assessments
Number of subjects: 1372

Group type: EXPERIMENTAL
Intervention: Overall healthcare worker services
Number of subjects: 1372
Study: 23468262

Group type: EXPERIMENTAL
Intervention: 1 µg/kg bolus of remifentanil
Number of subjects: 54

Group type: COMPARATOR
Intervention: 0.5 µg/kg bolus of remifentanil
Number of subjects: 54
Study: 21575095

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of differentiated adipocytes
Number of subjects: 31
Study: 19033260

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 826
Study: 17079789

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided placement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Palpation placement
Number of subjects: 60
Study: 15645904

Group type: EXPERIMENTAL
Intervention: Two-phase, calcium-containing, bicarbonate-based toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental, two-phase, calcium-containing, bicarbonate-free toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All three toothpastes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two calcium-containing toothpastes
Number of subjects: 0
Study: 11245647

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 703

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 703
Study: 8846523

Group type: EXPERIMENTAL
Intervention: Calcium acetate (5.04 ± 0.60 g daily, 10.1 ± 1.20 tablets of 500 mg)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (2.71 ± 0.48 g daily, 5.4 ± 0.95 capsules of 500 mg) with aluminum hydroxide (0.69 ± 0.27 g daily, 1.4 ± 0.55 tablets of 500 mg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Aluminum hydroxide
Number of subjects: 53
Study: 1659052

Group type: EXPERIMENTAL
Intervention: Oka/Merck varicella vaccine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22